[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 3 sources · 28 days · First seen · Last updated

Eli Lilly therapeutic pipeline expansion

Overview

Eli Lilly has been pursuing strategic expansions into new therapeutic fields, specifically mental health, immunology, and dermatology. In September 2026, the company completed its acquisition of AtaiBeckley, a biopharmaceutical firm focused on neuroplastogens for mental health conditions. A primary asset in this deal is BPL-003, an investigational therapy for treatment-resistant depression.

By October 2026, the company reported new clinical data from its Phase 3b TOGETHER-PsO study, showing that combining Taltz and Zepbound produces broader biomarker changes in patients with psoriasis and obesity compared to Taltz alone. Lilly also expanded its research through an $870 million agreement with Gate Bioscience to target disease-causing proteins and reinforced its presence in psychedelic medicine following the AtaiBeckley acquisition.

Entities

Eli Lilly · BPL-003 · Atai Beckley · AtaiBeckley · Compass Pathways

Timeline

  1. [BUSINESS] 2 sources
    Eli Lilly expands research in dermatology and psychedelics

    Eli Lilly reports positive Phase 3b data for combined Taltz and Zepbound treatments and continues to expand its pharmaceutical pipeline through major acquisitions and research partnerships.

  2. [BUSINESS] 2 sources
    Eli Lilly completes acquisition of AtaiBeckley

    Eli Lilly has finalized the acquisition of AtaiBeckley, gaining access to a clinical-stage mental health pipeline including BPL-003, an investigational therapy for treatment-resistant depression.

Sources

ad-hoc-news.de · finanznachrichten.de · pulse2.com